Send to

Choose Destination
J Pharm Policy Pract. 2019 Aug 14;12:18. doi: 10.1186/s40545-019-0179-9. eCollection 2019.

The Brazilian private pharmaceutical market after the first ten years of the generics law.

Author information

1Postgraduate Program in Epidemiology, Federal University of Pelotas, Rua Marechal Deodoro, 1160 3º piso, Pelotas, RS CEP 96.020-220 Brazil.
2Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 401 Park Drive, Suite 401, Boston, MA 02215 USA.
3Department of Surgery, Division of Thoracic Surgery, University of Massachusetts Medical School, 67 Belmont street, #201, Worcester, MA 01605 USA.
4Pharmacy School, Federal University of Rio de Janeiro, Campus Macaé, Av. Aluizio da Silva Gomes, 50, Novo Cavaleiros, Macaé, RJ 27930-560 Brazil.
5IQVIA, 210 Pentonville Rd, London, N1 9JY UK.



To describe changes in the private market for selected originators, branded generics ('similares'), and generic products during the 10 years following passage of the Brazilian Generics Law.


We analyzed longitudinal data collected by IQVIA® on quarterly sales by wholesalers to retail pharmacies in Brazil from 1998 through 2010, grouped by originators, branded generics, and generic products in three therapeutic classes (antibiotics, antidiabetics, and antihypertensives). Outcomes included market share (proportion of the total private market volume), sales volume per capita, prices and number of manufacturers by group.


In the private market share, generics became dominant in each therapeutic class but the speed of uptake varied. Originators consistently lost most market share while branded generics varied over time. By the end of the study period, generics were the most sold product type in all classes, followed by branded generics. The number of generic manufacturers increased in all classes, while branded generics increased just after the policy but then decreased slowly through the end of 2010. For approximately 50% of the antibiotics analyzed, branded generics and generics had lower prices than originators. For antidiabetics, branded generic and generic prices were quite similar during the period analyzed. Price trends for the various subclasses of antihypertensive exhibited very different patterns over time.


Sales of branded generics and originators decreased substantially in the three therapeutic classes analysed following the introduction of the generics policy in Brazil, but the time to market dominance of generics varied by class.


Brazil; Generic medicines; pharmaceutical policy; Market share; Prices

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center